[The effect of captopril on proteinuria in glomerular diseases]. 1990

Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

We evaluated the efficacy of an ACE inhibitor captopril (CAP) for the reduction of proteinuria in glomerular diseases, and tried to find the conditions in which urinary protein excretion was significantly decreased by this drug. Renin provocation test by CAP (C-test) was performed, and the result was compared to the effect on proteinuria. In 33 patients with proteinuria, ranging from 1.1 to 14.1 g/day, CAP was administered. Urinary protein excretion was reduced from 3.6 +/- 0.6 to 2.8 +/- 0.4 g/day (mean +/- SEM, p less than 0.01) after 2 weeks. The decrease in urinary protein was significant when renal function was moderately impaired (30 less than or equal to Ccr less than 60 ml/min) or patients were on a salt diet less than 7 g of NaCl daily. Reduction of urinary protein excretion by 2-week treatment of CAP was correlated with the result of C-test (r = 0.874, p less than 0.025). The long-term follow up for more than 6 months also suggested that CAP delayed the deterioration of renal function. Thus, CAP was proved effective in treating proteinuria, and C-test might give us an information of its proteinuria-suppressing effect in an individual case. But its efficacy was observed only in patients with moderately-reduced renal function or on low-salt diet. Therefore, we should select the cases carefully to expect the effect of CAP for the reduction of proteinuria.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D004039 Diet, Sodium-Restricted A diet which contains very little sodium chloride. It is prescribed by some for hypertension and for edematous states. (Dorland, 27th ed) Diet, Low-Salt,Diet, Low-Sodium,Diet, Salt-Free,Diet, Low Salt,Diet, Low Sodium,Diet, Salt Free,Diet, Sodium Restricted,Diets, Low-Salt,Diets, Low-Sodium,Diets, Salt-Free,Diets, Sodium-Restricted,Low-Salt Diet,Low-Salt Diets,Low-Sodium Diet,Low-Sodium Diets,Salt-Free Diet,Salt-Free Diets,Sodium-Restricted Diet,Sodium-Restricted Diets
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
September 1992, Yonsei medical journal,
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
August 1993, Nihon Jinzo Gakkai shi,
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
August 1986, The New England journal of medicine,
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
December 1985, The New England journal of medicine,
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
July 2013, Pediatric nephrology (Berlin, Germany),
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
April 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
January 1991, Archivos de investigacion medica,
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
January 1988, Therapia Hungarica (English edition),
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
April 1987, Orvosi hetilap,
Y Yamaguchi, and T Saito, and K Obara, and T Ootaka, and N Akiu, and H Sato, and Y Kinoshita, and J Seino, and K Tsunoda, and M Yasujima
January 1990, American journal of nephrology,
Copied contents to your clipboard!